Loading
A phase 3 trial of HPV quadrivalent vaccine in penile cancer, run by Shanghai Bovax Biotechnology Co., Ltd., active and no longer recruiting.
A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males is a phase 3 interventional study registered as NCT06465914 by Shanghai Bovax Biotechnology Co., Ltd., with 9000 participants enrolled, started 2024-07-11 and due to reach its primary completion in 2027-07-30. Interventions recorded: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Hansenula Polymorpha), Placebo. Conditions listed: Genital Wart, Penile Cancer, Anal Cancer, PIN-1. No results are recorded here; the registry entry is the source.
Shares Shanghai Bovax Biotechnology, HPV quadrivalent vaccine (types 6, 11, 16 and 18), Cancer interception vaccines, HPV & HBV vaccination.
Shares HPV quadrivalent vaccine (types 6, 11, 16 and 18), Cancer interception vaccines, HPV & HBV vaccination.
Shares Localised penile cancer (organ-confined, node-negative), Penile cancer, HPV & HBV vaccination.
Shares HPV quadrivalent vaccine (types 6, 11, 16 and 18), Localised penile cancer (organ-confined, node-negative), Penile cancer, HPV & HBV vaccination.
Shares Localised penile cancer (organ-confined, node-negative), Penile cancer.
Shares Localised penile cancer (organ-confined, node-negative), Penile cancer.
Shares Localised penile cancer (organ-confined, node-negative), Penile cancer, HPV & HBV vaccination.
Shares Shanghai Bovax Biotechnology, HPV quadrivalent vaccine (types 6, 11, 16 and 18), Penile cancer, HPV & HBV vaccination.